Seegene, Inc.

KOSDAQ 096530.KQ

Seegene, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 400.01 M

Seegene, Inc. Cash and Short-Term Investments is USD 400.01 M for the year ending December 31, 2023, a -16.14% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Seegene, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 476.98 M, a 20.36% change year over year.
Seegene, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 396.28 M, a 34.37% change year over year.
Seegene, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 294.92 M, a 417.68% change year over year.
Seegene, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 56.97 M, a 44.35% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 096530.KQ

Seegene, Inc.

CEO	Dr. Jong-Yoon Chun
IPO Date	Sept. 10, 2010
Location	South Korea
Headquarters	Taewon Building
Employees	63
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years